Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Heron Therapeutics (HRTX) Stock Price & Analysis

1,669 Followers

HRTX Stock Chart & Stats

$0.33-$0.03(-9.47%)
At close: 4:00 PM EST
$0.3$0.35$0.4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.32 - $0.36
52-Week Range
$0.26 - $1.58
Previous Close
$0.36
Volume
N/A
Average Volume (3M)
7.10M
Market Cap
$68.37M
Enterprise Value
$169.18M
Total Cash (Recent Filing)
$23.45M
Total Debt (Recent Filing)
$131.73M
Price to Earnings (P/E)
―
Beta
1.62
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.03
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Asset Sale Can Reduce Financial Pressure

The announced transaction could materially improve financial flexibility if completed as described, because cash proceeds are designated for facility repayment and additional shares, royalties, and earn-outs preserve potential future value from retained rights.

APONVIE Is Gaining Adoption

Rapid APONVIE sales, account growth, and share gains indicate expanding commercial adoption in surgical care. Broader P&T access and a growing procedure base can support durable demand and partially diversify the company beyond its largest product.

High Gross Margins And Improving Adjusted EBITDA

Gross margin near 70% provides a strong economic base for the commercial portfolio, while improved adjusted EBITDA suggests operating leverage. If product demand remains stable, this combination can support better earnings conversion as spending is managed.

Bears Say

CINVANTI Faces Generic-entry Risk

Potential generic competition threatens the largest revenue stream and could pressure product sales, pricing, and market share. The ongoing appeal does not remove the uncertainty, making future revenue durability and commercial planning more difficult.

Extremely Leveraged Capital Structure

Very high leverage leaves little equity cushion against operating setbacks and increases dependence on creditor support. Debt service, covenant requirements, and refinancing needs can constrain investment in commercialization while magnifying the impact of weaker sales.

The Company Remains Cash-flow Negative

Despite moderating cash burn, negative operating and free cash flow means the business is not yet self-funding. Continued reliance on financing or asset proceeds can limit strategic flexibility and leave less capacity to absorb product or legal setbacks.

Heron Therapeutics News

HRTX FAQ

What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $0.26 and its highest was $1.58 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $68.37M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 111 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Nov 09, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.005.
Is Heron Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 190,273,590 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went up 26.28%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Hedge funds hold Heron Therapeutics shares: the largest hedge-fund position in Heron Therapeutics is 71,885,181 shares, and hedge funds increased their holdings by 444.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology